Top-Rated StocksTop-RatedNYSE:GKOS Glaukos (GKOS) Stock Price, News & Analysis $102.43 +5.83 (+6.04%) Closing price 03/14/2025 03:59 PM EasternExtended Trading$101.02 -1.42 (-1.38%) As of 03/14/2025 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Glaukos Stock (NYSE:GKOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Glaukos alerts:Sign Up Key Stats Today's Range$97.75▼$103.3550-Day Range$96.32▼$161.5552-Week Range$84.08▼$163.71Volume1.09 million shsAverage Volume577,864 shsMarket Capitalization$5.79 billionP/E RatioN/ADividend YieldN/APrice Target$163.25Consensus RatingModerate Buy Company OverviewGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Read More… Remove Ads Glaukos Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreGKOS MarketRank™: Glaukos scored higher than 90% of companies evaluated by MarketBeat, and ranked 93rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingGlaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGlaukos has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Glaukos' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($1.08) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -35.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -35.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 10.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Glaukos' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.86% of the float of Glaukos has been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Glaukos has recently increased by 1.72%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-0.90 Percentage of Shares Shorted6.86% of the float of Glaukos has been sold short.Short Interest Ratio / Days to CoverGlaukos has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Glaukos has recently increased by 1.72%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment1.00 News SentimentGlaukos has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Glaukos this week, compared to 7 articles on an average week.Search Interest5 people have searched for GKOS on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,504,131.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Glaukos is held by insiders.Percentage Held by Institutions99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Glaukos' insider trading history. Receive GKOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter. Email Address GKOS Stock News HeadlinesTomas Navratil Sells 3,416 Shares of Glaukos Co. (NYSE:GKOS) StockFebruary 20, 2025 | insidertrades.comHere's Why You Should Retain Glaukos Stock in Your PortfolioMarch 13 at 7:59 PM | msn.comAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.March 15, 2025 | Altimetry (Ad)Glaukos, RadiusXR collaborate with Topcon Healthcare on vision testing platformMarch 11, 2025 | markets.businessinsider.comGlaukos Co. (NYSE:GKOS) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMarch 10, 2025 | americanbankingnews.comIs Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts?March 5, 2025 | msn.comMorgan Stanley Reaffirms Their Sell Rating on Glaukos (GKOS)February 26, 2025 | markets.businessinsider.comFDA gives Glaukos ‘Day 74’ notice for Epioxa NDA to treat keratoconusFebruary 24, 2025 | markets.businessinsider.comSee More Headlines GKOS Stock Analysis - Frequently Asked Questions How have GKOS shares performed this year? Glaukos' stock was trading at $149.94 at the beginning of the year. Since then, GKOS stock has decreased by 31.7% and is now trading at $102.4310. View the best growth stocks for 2025 here. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) issued its earnings results on Thursday, February, 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. The medical instruments supplier had revenue of $105.50 million for the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative trailing twelve-month return on equity of 16.53% and a negative net margin of 39.04%. When did Glaukos IPO? Glaukos (GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. Who are Glaukos' major shareholders? Top institutional shareholders of Glaukos include FMR LLC (11.08%), Vanguard Group Inc. (10.84%), Wellington Management Group LLP (3.92%) and Invesco Ltd. (2.65%). Insiders that own company stock include Joseph E Gilliam, Tomas Navratil, Thomas William Burns, Alex R Thurman, Marc Stapley, Mark J Foley, Gilbert H Kliman and Aimee S Weisner. View institutional ownership trends. How do I buy shares of Glaukos? Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA) and Netflix (NFLX). Company Calendar Last Earnings2/20/2025Today3/15/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:GKOS CIK1192448 Webwww.glaukos.com Phone(949) 367-9600Fax949-367-9984Employees780Year FoundedN/APrice Target and Rating Average Stock Price Target$163.25 High Stock Price Target$200.00 Low Stock Price Target$120.00 Potential Upside/Downside+59.4%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,660,000.00 Net Margins-39.04% Pretax Margin-41.24% Return on Equity-16.53% Return on Assets-10.61% Debt Debt-to-Equity Ratio0.19 Current Ratio5.54 Quick Ratio4.71 Sales & Book Value Annual Sales$383.48 million Price / Sales15.11 Cash FlowN/A Price / Cash FlowN/A Book Value$9.46 per share Price / Book10.83Miscellaneous Outstanding Shares56,567,000Free Float51,608,000Market Cap$5.79 billion OptionableOptionable Beta0.99 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NYSE:GKOS) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Glaukos Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Glaukos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.